Table 3.
Minimum inhibitory concentration of Mycobacterium abscessus subsp. abscessus (n=67) and Mycobacterium abscessus subsp. massiliense (n=140)
|
Antibiotic |
Organism |
MIC50 |
MIC90 |
Sensitive |
Intermediate |
Resistant |
|---|---|---|---|---|---|---|
|
Amikacin |
Mab |
16 |
16 |
94.0 % |
3.0% |
3.0% |
|
Mma |
16 |
32 |
94.3 % |
5.7% |
0.0% |
|
|
Cefoxitin |
Mab |
64 |
64 |
1.5 % |
83.6% |
14.9% |
|
Mma |
64 |
64 |
3.6 % |
92.1% |
4.3% |
|
|
Ciprofloxacin |
Mab |
>4 |
>4 |
0.0 % |
6.0% |
94.0% |
|
Mma |
>4 |
>4 |
0.7 % |
3.6% |
95.7% |
|
|
Doxycycline |
Mab |
>16 |
>16 |
0.0 % |
0.0% |
100.0% |
|
Mma |
>16 |
>16 |
0.7 % |
0.7% |
98.6% |
|
|
Imipenem |
Mab |
16 |
32 |
4.5 % |
66.7% |
28.8% |
|
Mma |
15 |
32 |
2.1 % |
75.0% |
22.9% |
|
|
Linezolid |
Mab |
16 |
>32 |
32.8% |
22.4% |
44.8% |
|
Mma |
16 |
>32 |
22.9% |
32.1% |
45.0% |
|
|
Moxifloxacin |
Mab |
>8 |
>8 |
0.0% |
1.5% |
98.5% |
|
Mma |
>8 |
>8 |
0.0% |
1.4% |
98.6% |
|
|
Trimethoprim-sulphamethoxazole |
Mab |
8 |
>8 |
26.9% |
n/a |
73.1% |
|
Mma |
8 |
>8 |
18.7% |
n/a |
81.3% |
|
|
Tobramycin |
Mab |
16 |
>16 |
0.0% |
0.0% |
100.0% |
|
Mma |
16 |
>16 |
0.0% |
0.0% |
100.0% |
|
|
Minocycline |
Mab |
>8 |
>8 |
0.0% |
0.0% |
100.0% |
|
Mma |
>8 |
>8 |
0.7% |
8.6% |
90.7% |
|
|
Tigecycline |
Mab |
0.5 |
1 |
n/a |
n/a |
n/a |
|
Mma |
0.5 |
1 |
n/a |
n/a |
n/a |
|
|
Clofazimine |
Mab |
0.25 |
0.25 |
n/a |
n/a |
n/a |
|
Mma |
0.12 |
0.25 |
n/a |
n/a |
n/a |
|
|
Bedaquiline |
Mab |
0.06 |
0.12 |
n/a |
n/a |
n/a |
|
Mma |
0.06 |
0.12 |
n/a |
n/a |
n/a |
|
|
Eravacycline |
Mab |
0.06 |
0.25 |
n/a |
n/a |
n/a |
|
Mma |
0.12 |
0.25 |
n/a |
n/a |
n/a |
|
|
Rifabutin |
Mab |
16 |
16 |
n/a |
n/a |
n/a |
|
Mma |
16 |
32 |
n/a |
n/a |
n/a |
MIC distribution in mg l−1; MIC50: MIC required to inhibit the growth of 50 % of included isolates; MIC90: MIC required to inhibit the growth of 90 % of included isolates. Mab: M. abscessus subsp. abscessus; Mma: M. abscessus subsp. massiliense. N/A, CLSI and EUCAST interpretive breakpoints not available.
n, number of study isolates.